By the end of 2020 (Strategic Plan)By end of 2020:
• clinical plans finalized and submitted to PMDA for 2 clinical trials to be launched in Japan (financed by partner(s));
• clinical plans finalized and submitted to regulators for 2 clinical trials to be launch in China (financed by YOFOTO);
• plans from Shiseido re pivotal study of RCH-01 in Japan;
• dossier submitted for CE mark of RepliCel injector and consumables;
• new clinical study launched on use of the dermal injector for a large-market application; in addition to having a product to be launched imminently on the market in Europe and Hong Kong.